Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) had its price target decreased by analysts at Morgan Stanley from $7.00 to $5.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an "equal weight" rating on the stock. Morgan Stanley's price target points to a potential upside of 56.74% from the company's current price.
KPTI has been the topic of a number of other reports. HC Wainwright lowered their price target on shares of Karyopharm Therapeutics from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Tuesday, January 10th. StockNews.com cut Karyopharm Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday, November 30th. Piper Sandler initiated coverage on Karyopharm Therapeutics in a research report on Thursday, January 19th. They issued an "overweight" rating and a $8.00 price target on the stock. SVB Leerink cut their price objective on shares of Karyopharm Therapeutics from $6.00 to $5.00 and set a "market perform" rating for the company in a research report on Tuesday, January 10th. Finally, Royal Bank of Canada raised shares of Karyopharm Therapeutics from a "sector perform" rating to an "outperform" rating and raised their target price for the company from $7.00 to $10.00 in a report on Friday, November 4th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $9.33.
Get Karyopharm Therapeutics alerts:Karyopharm Therapeutics Stock Up 1.9 %
Shares of Karyopharm Therapeutics stock traded up $0.06 on Friday, hitting $3.19. The stock had a trading volume of 267,941 shares, compared to its average volume of 3,391,519. The stock has a market cap of $258.88 million, a price-to-earnings ratio of -2.80 and a beta of 0.03. Karyopharm Therapeutics has a twelve month low of $2.45 and a twelve month high of $14.73. The business's 50 day moving average is $3.71 and its two-hundred day moving average is $4.57.
Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.11. The firm had revenue of $36.15 million during the quarter, compared to analyst estimates of $34.82 million. As a group, equities analysts predict that Karyopharm Therapeutics will post -1.93 earnings per share for the current fiscal year.Institutional Trading of Karyopharm Therapeutics
A number of hedge funds have recently made changes to their positions in the company. Dupont Capital Management Corp bought a new position in Karyopharm Therapeutics in the 4th quarter valued at approximately $78,000. Bank of New York Mellon Corp grew its stake in shares of Karyopharm Therapeutics by 4.4% in the third quarter. Bank of New York Mellon Corp now owns 298,991 shares of the company's stock worth $1,632,000 after purchasing an additional 12,610 shares during the last quarter. Balyasny Asset Management LLC increased its holdings in Karyopharm Therapeutics by 592.0% in the third quarter. Balyasny Asset Management LLC now owns 595,558 shares of the company's stock valued at $3,252,000 after purchasing an additional 509,499 shares during the period. BNP Paribas Arbitrage SNC increased its holdings in Karyopharm Therapeutics by 30.5% in the third quarter. BNP Paribas Arbitrage SNC now owns 762,520 shares of the company's stock valued at $4,163,000 after purchasing an additional 178,232 shares during the period. Finally, Alliancebernstein L.P. raised its position in Karyopharm Therapeutics by 17.0% during the 3rd quarter. Alliancebernstein L.P. now owns 138,130 shares of the company's stock worth $754,000 after purchasing an additional 20,100 shares during the last quarter. 96.13% of the stock is owned by institutional investors and hedge funds.
About Karyopharm Therapeutics
(Get Rating)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
Further Reading
- Get a free copy of the StockNews.com research report on Karyopharm Therapeutics (KPTI)
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- PCE Indicates Slowdown In Spending, Economy Weakens
- Microsoft's Comeback Is Now Underway
- Can Amazon Recover Amid Tech Stock Sell-off?
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.